Tumors shed fragmented DNA and nucleic acids into the blood, generally during apoptosis.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226.Obstet Gynecol. 2020; 136: e48-e69
- Presence of fetal DNA in maternal plasma and serum.Lancet. 1997; 350: 485-487
- The emerging role of cell-free DNA as a molecular marker for cancer management.Biomol Detect Quantif. 2019; 17: 100087
- Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin.Cell. 2016; 164: 57-68
- Detection of circulating tumor DNA in early- and late-stage human malignancies.Sci Transl Med. 2014; 6: 224ra224
- Comparison of methods for the isolation of cell-free DNA from cell culture supernatant.Tumour Biol. 2020; 42 (1010428320916314)
- Preanalytical variables that affect the outcome of cell-free DNA measurements.Crit Rev Clin Lab Sci. 2020; 57: 484-507
- Cell-free DNA in cancer: current insights.Cell Oncol. 2019; 42: 13-28
- Non-blood circulating tumor DNA detection in cancer.Oncotarget. 2017; 8: 69162-69173
- Integrating circulating miRNA analysis in the clinical management of lung cancer: Present or future?.Mol Aspects Med. 2020; 72: 100844
- Pre-analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients.Mol Oncol. 2020; 14: 1001-1015
- Harmonizing Cell-Free DNA Collection and Processing Practices through Evidence-Based Guidance.Clin Cancer Res. 2020; 26: 3104-3109
- Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical Conditions.Mol Diagn Ther. 2020; 24: 113-124
- Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions.Mol Oncol. 2017; 11: 295-304
- Fundamentals of liquid biopsies in metastatic prostate cancer: from characterization to stratification.Curr Opin Oncol. 2020; 32: 527-534
- Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients.J Mol Diagn. 2018; 20: 883-892
- Early detection of cancer using circulating tumor DNA: biological, physiological and analytical considerations.Crit Rev Clin Lab Sci. 2019; : 1-17
- Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study.Cell Death Dis. 2019; 10: 534
- Optimized (Pre) Analytical Conditions and Workflow for Droplet Digital PCR Analysis of Cell-Free DNA from Patients with Suspected Lung Carcinoma.J Mol Diagn. 2019; 21: 895-902
- Stability of cell-free DNA from maternal plasma isolated following a single centrifugation step.Prenat Diagn. 2014; 34: 1283-1288
- A Study of Pre-Analytical Variables and Optimization of Extraction Method for Circulating Tumor DNA Measurements by Digital Droplet PCR.Cancer Epidemiol Biomarkers Prev. 2019; 28: 909-916
- Effects of blood-processing protocols on cell-free DNA quantification in plasma.Clin Chem. 2003; 49: 525-526
- Incorporating liquid biopsies into treatment decision-making: obstacles and possibilities.Drug Discov Today. 2019; 24: 1715-1719
- High-throughput isolation of circulating tumor DNA: a comparison of automated platforms.Mol Oncol. 2019; 13: 392-402
- Evaluation of commercial kits for purification of circulating free DNA.Cancer Genet. 2018; 228-229: 21-27
- Liquid biopsies: genotyping circulating tumor DNA.J Clin Oncol. 2014; 32: 579-586
- Current and future perspectives of liquid biopsies in genomics-driven oncology.Nat Rev Genet. 2019; 20: 71-88
- Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management.Comput Struct Biotechnol J. 2018; 16: 370-378
- High-throughput droplet digital PCR system for absolute quantitation of DNA copy number.Anal Chem. 2011; 83: 8604-8610
- Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.Cancer Discov. 2017; 7: 1394-1403
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.Nat Med. 2014; 20: 548-554
- Integrated digital error suppression for improved detection of circulating tumor DNA.Nat Biotechnol. 2016; 34: 547-555
- Direct detection of early-stage cancers using circulating tumor DNA.Sci Transl Med. 2017; 9: eaan2415
- Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection.Nat Rev Clin Oncol. 2018; 15: 577-586
- Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.Sci Transl Med. 2012; 4: 136ra168
- Detection and localization of surgically resectable cancers with a multi-analyte blood test.Science. 2018; 359: 926-930
- Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA.Nat Genet. 2017; 49: 635-642
- Liquid biopsies: DNA methylation analyses in circulating cell-free DNA.J Genet Genomics. 2018; 45: 185-192
- Whole-genome bisulfite sequencing of cell-free DNA identifies signature associated with metastatic breast cancer.Clin Epigenet. 2015; 7: 100
- Genome-scale detection of hypermethylated CpG islands in circulating cell-free DNA of hepatocellular carcinoma patients.Cell Res. 2015; 25: 1250-1264
- Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA.Ann Oncol. 2020; 31: 745-759
- Expression of circulating microRNA-20a and let-7a in esophageal squamous cell carcinoma.World J Gastroenterol. 2015; 21: 4660-4665
- MicroRNAs as potential biomarkers in cancer: opportunities and challenges.Biomed Res Int. 2015; 2015: 125094
- Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer.Clin Chem Lab Med. 2011; 49: 1591-1603
- Detection methods for microRNAs in clinic practice.Clin Biochem. 2013; 46: 869-878
- Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing (ASCEND).(Available at:)
- Liquid biopsy enters the clinic - implementation issues and future challenges.Nat Rev Clin Oncol. 2021; 18: 297-312
- Cancer detection: Seeking signals in blood.Science. 2018; 359: 866-867
- Transforming the landscape of early cancer detection using blood tests-Commentary on current methodologies and future prospects.Br J Cancer. 2021; 124: 1475-1477
- Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention.Science. 2020; : 369
- (Available at:)
- Genome-wide cell-free DNA fragmentation in patients with cancer.Nature. 2019; 570: 385-389
- Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma.Clin Chem. 2014; 60: 1183-1191
- Integrating genomic features for non-invasive early lung cancer detection.Nature. 2020; 580: 245-251
- NCCN Guidelines Non-Small Cell Lung Cancer v4.2021.(Available at:)https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdfDate: 2021Date accessed: April 28, 2021
- Profile of the Roche cobas(R) EGFR mutation test v2 for non-small cell lung cancer.Expert Rev Mol Diagn. 2017; 17: 209-215
- Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice.Nat Rev Clin Oncol. 2021; 18: 56-62
- Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer.Clin Cancer Res. 2019; 25: 4691-4700
- Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.N Engl J Med. 2019; 380: 1929-1940
- Prostate cancer and PARP inhibitors: progress and challenges.J Hematol Oncol. 2021; 14: 51
- Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.Sci Transl Med. 2015; 7: 302ra133
- Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.JAMA Oncol. 2019; 5: 1473-1478
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.Nature. 2017; 545: 446-451
- Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma.J Clin Oncol. 2019; 37: 1547-1557
- Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence.Clin Cancer Res. 2019; 25: 4255-4263
- Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.Nat Cancer. 2020; 1: 873-881
- Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers.Nat Med. 2019; 25: 1415-1421
- Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer.Sci Rep. 2020; 10: 14704
- Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.Blood. 2015; 126: 9-16
- Age-related clonal hematopoiesis associated with adverse outcomes.N Engl J Med. 2014; 371: 2488-2498
- Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease.N Engl J Med. 2017; 377: 111-121
- Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states.Lancet Haematol. 2020; 7: e73-e81
- DNA methyltransferases and their roles in tumorigenesis.Biol Res. 2017; 5: 1
- Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology.JAMA Oncol. 2017; 3: 996-998
- Orthogonal Comparison of Four Plasma NGS Tests With Tumor Suggests Technical Factors are a Major Source of Assay Discordance.JCO Precision Oncol. 2019; : 1-9
- Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC’s Analytical Variables Working Group.Clin Chem. 2020; 66: 1156-1166
- Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late.Diagnostics. 2021; 11: 103
- Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.J Clin Oncol. 2018; 36: 1631-1641
- Technical Evaluation of Commercial Mutation Analysis Platforms and Reference Materials for Liquid Biopsy Profiling.Cancers (Basel). 2020; 12
- International liquid biopsy standardization alliance white paper.Crit Rev Oncol Hematol. 2020; 156: 103112
- Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.BMC Cancer. 2020; 20: 945
- Analytical validation of an error-corrected ultra-sensitive ctDNA next-generation sequencing assay.BioTechniques. 2020; 69: 133-140
- Considerations and quality controls when analyzing cell-free tumor DNA.Biomol Detect Quantif. 2019; 17: 100078
- Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients.Mol Med Rep. 2017; 16: 1157-1166
- Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019.J Natl Compr Canc Netw. 2020; 18: 866-872
- Analysis of the Cost-Effectiveness of Liquid Biopsy to Determine Treatment Change in Patients with Her2-Positive Advanced Breast Cancer in Colombia.Clin Outcomes Res. 2020; 12: 115-122
- Nuclear Acids In Human Blood Plasma.C R Seances Soc Biol Fil. 1948; 142: 241-243
Article Info
Footnotes
This article previously appeared in Advances in Molecular Pathology, Volume 4, Issue 1, November 2021.
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
